- Home
- WVE vs DNN Comparison
WVE vs DNN Comparison
Compare WVE & DNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WVE
- DNN
- Stock Information
- Founded
- WVE 2012
- DNN 1936
- Country
- WVE Singapore
- DNN Canada
- Employees
- WVE N/A
- DNN N/A
- Industry
- WVE Biotechnology: Pharmaceutical Preparations
- DNN Other Metals and Minerals
- Sector
- WVE Health Care
- DNN Basic Materials
- Exchange
- WVE Nasdaq
- DNN Nasdaq
- Market Cap
- WVE 2.1B
- DNN 1.8B
- IPO Year
- WVE 2015
- DNN 1997
- Fundamental
- Price
- WVE $10.99
- DNN $1.88
- Analyst Decision
- WVE Strong Buy
- DNN Strong Buy
- Analyst Count
- WVE 10
- DNN 2
- Target Price
- WVE $21.60
- DNN $3.00
- AVG Volume (30 Days)
- WVE 1.0M
- DNN 25.0M
- Earning Date
- WVE 03-05-2025
- DNN 02-27-2025
- Dividend Yield
- WVE N/A
- DNN N/A
- EPS Growth
- WVE N/A
- DNN N/A
- EPS
- WVE N/A
- DNN N/A
- Revenue
- WVE $53,610,000.00
- DNN $2,920,167.00
- Revenue This Year
- WVE N/A
- DNN $226.79
- Revenue Next Year
- WVE $48.58
- DNN $133.88
- P/E Ratio
- WVE N/A
- DNN N/A
- Revenue Growth
- WVE N/A
- DNN N/A
- 52 Week Low
- WVE $3.50
- DNN $1.40
- 52 Week High
- WVE $16.74
- DNN $2.47
- Technical
- Relative Strength Index (RSI)
- WVE 34.06
- DNN 41.80
- Support Level
- WVE $10.57
- DNN $1.89
- Resistance Level
- WVE $12.03
- DNN $1.98
- Average True Range (ATR)
- WVE 0.69
- DNN 0.10
- MACD
- WVE -0.17
- DNN -0.00
- Stochastic Oscillator
- WVE 12.54
- DNN 22.50
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
About DNN Denison Mines Corp (Canada)
Denison Mines Corp is a uranium exploration and development company with interests focused in the Athabasca Basin region of northern Saskatchewan, Canada. The company has an effective 95% interest in its flagship Wheeler River Uranium Project, which is the largest undeveloped uranium project in the infrastructure-rich eastern portion of the Athabasca Basin region of northern Saskatchewan. The company is also engaged in mine decommissioning and environmental services through its Closed Mines group, which manages its Elliot Lake reclamation projects and provides third-party post-closure mine care and maintenance services.